Relay Therapeutics is a biotechnology company focused on transforming the drug discovery process through its innovative approach that combines advanced computational technologies and biophysics
The company specializes in developing precision medicines aimed at treating cancer and other serious diseases by designing therapeutics that specifically address the unique molecular features of patients' diseases. By leveraging its proprietary platform, Relay Therapeutics seeks to enhance the understanding of protein dynamics and interactions, enabling the identification of better drug candidates with improved efficacy and safety profiles.
Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats:
CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, February 26, 2025.
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 7:30 a.m. PT.
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in the following upcoming fireside chats:
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 6, 2024.
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.
Relay Therapeutics shares interim data for RLY-2608 from the ReDiscover study, showing a 57% clinical benefit rate. Oppenheimer downgrades Relay Therapeutics from Outperform to Perform, citing concerns about competitor data and efficacy challenges.
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.
CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten public offering of 28,571,429 shares of its common stock at a public offering price of $7.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 4,285,714 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $200 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Relay Therapeutics.
Monday, Relay Therapeutics Inc. (NASDAQRLAY) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study, to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of RLY-2608 alone, in combination with fulvestrant, and combinati
